Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and the sacroiliac joints (SI). It makes part of the “seronegative spondyloarthropathies” or spondyloarthritides (SpA). SpA describes a group of inflammatory arthritis diseases that are clinically and genetically related, but have distinct features from one another.
References and Further Reading
- Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983–2002. Rheumatology (Oxford). 2004;43(5):615–8.Google Scholar
- Baraliakos X, Kivitz AJ, Deodhar AA, MEASURE 1 Study Group, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36:50–5.PubMedGoogle Scholar
- Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282–98.CrossRefGoogle Scholar